David Muth was most recently the President & CEO of Croma Pharmaceuticals Inc., a private medical device/specialty pharmaceutical company. At Croma he developed and executed the strategic plan to establish N. American operations, gained approval of and launched 11 medical devices while building a pan Canadian Ophthalmology sales organization. In the US, he managed the filing of 2 IDE’s and 1 NDA and negotiated numerous global business development deals. Prior to Croma, Mr. Muth was the Global Head of Business Development – Pharmaceuticals for Bausch & Lomb where he negotiated and executed numerous BD deals including company/products acquisitions and in-licensed a portfolio of programs, which were key components of B&L’s valuation leading to Valeant’s $8.7B acquisition. Additionally, Mr. Muth served as the President and Chief Executive Officer of Osmotica Pharmaceutical Corp. where he built a CNS pipeline and directed the successful co-development of AllegraD-24 hrs. for Sanofi-Aventis. As the Senior Vice President of Business Operations at NABI Biopharmaceuticals, he developed and implemented the strategy that transitioned the company from a plasma supplier into a fully integrated biopharmaceutical company. During his tenure, he led a team that significantly grew pharmaceutical sales, built a natural hematological/oncology sales/marketing organization, launched four products, three of which he was responsible for in-licensing. Prior to this, Mr. Muth had a distinguished 17 year career with Johnson & Johnson in a variety of senior management assignments. He held positions spanning all commercial functions, including marketing research, sales, product management, new product development, and corporate development. In addition, Mr. Muth was responsible for the successful launch of three market leading pharmaceutical products: Terazol®,Ortho Cyclen® and Ortho Tri-Cyclen®. Mr. Muth holds an MBA in Finance as well as a MBA in Pharmaceutical Marketing.